U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131254) titled 'GT719 Injection for CD19 Positive Recurrent/Refractory Adult B-cell Malignancies' on June 26.
Brief Summary: This study is a prospective single-arm open-label phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 34 subjects will be enrolled in this study.
Study Start Date: Sept. 25, 2024
Study Type: INTERVENTIONAL
Condition:
Hematological Malignancy (Leukemia- Lymphoma)
Interventi...